久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

US EUROPE AFRICA ASIA 中文
Business / Q and A with CEO

Biotech leader continues fast innovation

By Wang Hongyi (China Daily) Updated: 2016-11-11 07:50

Biotech leader continues fast innovation

Severin Schwan, chief executive officer of Roche Group. PROVIDED TO CHINA DAILY

Roche Group looks to grow and change with the country's ever-evolving healthcare industry

Global biotechnology company Roche Group is committed to driving innovation forward in China, which offers a market of 1.3 billion people. With its research and development capabilities in pharmaceuticals and diagnostics, the company has positioned itself to promote personalized healthcare and contribute to China's precision medicine initiatives. Roche's CEO Severin Schwan shared his insights with China Daily reporter Wang Hongyi.

Could you describe Roche's R&D capacity, both globally and in China? What partnerships has Roche already built here?

As a world-leading biotechnology company, we are very much led by science and driven by innovation. We lead the industry with advances in personalized healthcare and our strong oncology portfolio.

R&D receives a greater share of our spending than marketing. On the group level, we spent 9.3 billion Swiss francs ($9.5 billion) on R&D in 2015, which was 19 percent of our turnover. We have consistently been among the top five R&D spenders worldwide, in any industry, since 2009.

Today, we have more than 330 employees in R&D in China. Over the past decades, we've trained a group of outstanding interdisciplinary researchers, leading to highly promising results through collaborations with Chinese companies and academic institutions.

What are your expectations for the new innovation center in Shanghai, which had its groundbreaking ceremony last week?

Last year, we invested 860 million yuan ($126.7 million) in constructing the new laboratory building for the innovation center in Shanghai. The new facility will provide 220 modular workspaces in 14,000 square meters of floor space. We expect it to be completed in 2018.

The focus of our innovation center is very much aligned with the diseases that have a high unmet medical need in China, such as Hepatitis B, which is one of the most prominent diseases in the country.

We hope the new innovation center will spur collaboration between Roche and local research institutions, helping to attract top research talents from both China and overseas.

Our aim is to develop outstanding new drugs for patients in Asia and around the world, and address the currently unmet needs of patients with infectious diseases and those related to immunology and inflammation, thus enhancing our long-term commitment to driving innovation in China.

What is Roche's position on personalized healthcare?

Personalized healthcare is about providing the right treatment for the right patient at the right time. With our combined strength in diagnostics and pharmaceuticals, we are uniquely positioned to further advance personalized healthcare.

In 2006, we made personalized healthcare central to our Roche Group Strategy. This focuses on integrating the knowledge in our pharmaceuticals and diagnostics divisions, and drawing on this knowledge throughout the R&D process, from early research to approval of new diagnostic tests and medicines, as well as their use by patients.

So far, we are the top player in oncology and in vitro diagnostics, drawing from decades of experience in molecular biology.

Today, we are developing two-thirds of our R&D projects with companion diagnostics, which greatly increases efficiency.

In 2015, Roche entered a broad strategic collaboration with Foundation Medicine, a leader in the field of molecular information in oncology, and began to use the latter's innovative genomic sequencing technology to accurately detect the oncogenic mutations in different patients and more effectively help oncologists to find highly-targeted therapies for cancer patients.

In January 2016, Roche announced its cooperation with Flatiron Health in integrating the immense "real world data" and using high-quality healthcare data and advanced analytics to improve both the development of medicines and the quality of treatment decisions.

The cooperation with Foundation Medicine in genomic data and the alliance with Flatiron Health in real world data strengthen Roche's access to innovation and new technologies and drive its commitment to more targeted treatments that, ultimately, make personalized healthcare a reality.

How will Roche promote personalized healthcare in China? What are the difficulties or challenges ahead?

Our diagnostics and pharmaceuticals teams are driving personalized healthcare in China. Roche China Biomarker Team is the first dedicated group in the industry to conduct biomarker studies, focusing on promoting cutting-edge science and technology. The team is mainly engaged in detecting biomarkers and using these techniques in product R&D.

We also provide training on personalized diagnosis and treatment for over 8,000 pathologists and over 4,000 pathology technicians in more than 600 hospitals, laying a solid foundation to improve personalized healthcare in China in the future.

Today, China already has leading companies in genome sequencing and a strong science community. I believe that China has full potential to realize personalized healthcare.

To turn personalized healthcare from a vision to reality is a long journey. The need to improve diagnosis and genetic testing, and the current lack of good quality patient data are problems that should be addressed. We are committed to supporting the Chinese government in overcoming these challenges.

How do you view China's rapid economic growth and its recent slowdown? Will this affect Roche's development in this market?

As one of the first multinational companies to enter China 20 years ago, we've witnessed the country's fastgrowth economy and its booming healthcare market.

The recent slowdown is a sign of China's transition to a new normal, toward building a more sustainable economy based on the consumption and service industries. A high value-added sector such as healthcare can be a new pillar of economic growth in this model.

With the slowing of economic growth, cost containment measures on off-patent drugs and the delayed launch of new drugs, 2015 is the first year since 2005 that the Chinese pharmaceutical industry is facing single-digit growth.

Despite short-term challenges, I am optimistic about the market's growth potential. With an aging population, China's demand for high-end healthcare and treatment for chronic diseases has increased rapidly over the past few years, in response to elderly patients' healthcare needs.

As part of its healthcare reform, the Chinese government is increasing overall spending on healthcare to broaden reimbursement coverage, especially for critical illnesses, and accelerating new drug approvals.

In the short term, we will benefit from expanded healthcare and reimbursement coverage for critical illnesses. In the mid-to-long term, we anticipate our business to grow more quickly, benefiting from the launch of new drugs.

How would you evaluate China's performance globally? Will Roche increase its investment in China?

China remains one of our most important markets globally. We have invested considerably to build a full value chain in China from R&D and manufacturing through to commercialization.

In diagnostics, China is already the second-largest country for us. In pharmaceuticals, China is our third-largest national market.

We recognize that China's pharmaceutical market environment is facing a challenging phase in the short term. However with our strong pipeline and dedicated people, we are confident about our long-term growth prospects by bringing more innovative products to China to benefit more patients.

What do you think of the opportunities and challenges facing your company amid recent healthcare reform? How does Roche fit into the national strategy of "building a healthy China"?

Since 2009, China's healthcare reforms have had far-reaching implications for the industry's long-term development.

The positive moves toward a more transparent and effective review process and capability building at the China Food and Drug Administration are promising for Chinese patients, as well as for innovation-driven companies like us.

We are very encouraged about the update to the National Reimbursed Drug List and hope that national reimbursement coverage can be broadened to critical illnesses.

There remain affordability challenges in China, but we are optimistic that with joint efforts from multiple stakeholders, including the Chinese government and companies like us, more and more patients will have the opportunity to access high-quality treatment.

Roche has been actively working together with different stakeholders, such as local governments, charity foundations, NGOs and insurance companies. We are looking to address unmet patient needs through reimbursement listings on the provincial and city level, patient access programs and private insurance offerings.

How do you motivate international teams?

I think people should be given more space and chances to increase their creativity.

In an organization, people should not be told what to do or what not to do. They should be given opportunities to make full use of their potential.

During this process, a leader should work to encourage them to achieve greater innovation rather than allocate them more tasks.

Hot Topics

Editor's Picks
...
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    国产日韩欧美a| 亚洲天堂av老司机| 国产福利91精品一区| 国产偷v国产偷v亚洲高清| 9色porny自拍视频一区二区| 亚洲免费av网站| 欧美精品在线一区二区| 日本中文字幕一区二区视频| 精品日韩一区二区| 成人在线综合网| 一区二区在线免费观看| 日韩一级视频免费观看在线| 国产高清视频一区| 亚洲免费av高清| 日韩午夜三级在线| 成熟亚洲日本毛茸茸凸凹| 一区二区三区在线影院| 91精品国产综合久久香蕉的特点| 激情小说欧美图片| 亚洲人午夜精品天堂一二香蕉| 欧美乱妇一区二区三区不卡视频| 国产麻豆日韩欧美久久| 亚洲欧美日韩国产成人精品影院| 911精品国产一区二区在线| 国产综合色精品一区二区三区| 中文字幕一区二区三区在线观看 | 精品视频资源站| 狠狠久久亚洲欧美| 亚洲免费在线视频一区 二区| 91精品国产高清一区二区三区| 国产露脸91国语对白| 一区二区三区在线观看动漫| 精品久久久久久亚洲综合网| 色婷婷精品久久二区二区蜜臂av| 久久精品国产99国产精品| 综合久久国产九一剧情麻豆| 日韩美女一区二区三区四区| 成人短视频下载| 免费在线观看精品| 国产精品久久久久婷婷| 欧美一区二区网站| 99麻豆久久久国产精品免费| 蜜臀av性久久久久蜜臀aⅴ四虎 | 亚洲一卡二卡三卡四卡五卡| 国产午夜精品久久久久久久 | 蜜桃视频免费观看一区| 亚洲视频免费在线观看| 精品国产123| 欧美在线制服丝袜| 国产999精品久久久久久| 日韩国产在线一| 自拍av一区二区三区| 欧美va亚洲va| 欧美日本一区二区在线观看| 成人app软件下载大全免费| 蜜臀av性久久久久蜜臀aⅴ流畅| 亚洲人成人一区二区在线观看| 2017欧美狠狠色| 欧美妇女性影城| 色综合天天综合网天天看片| 国产精品一级黄| 蜜臀久久久99精品久久久久久| 一区二区免费在线播放| 国产精品午夜电影| 久久精品一区二区| 日韩欧美国产wwwww| 91福利在线观看| 成人丝袜高跟foot| 久久成人精品无人区| 亚洲高清一区二区三区| 国产精品久久久久7777按摩| 久久午夜电影网| 日韩视频不卡中文| 欧美日韩国产首页| 在线观看日韩高清av| www.欧美日韩| 国产xxx精品视频大全| 极品少妇xxxx精品少妇| 男女激情视频一区| 免费的成人av| 日韩精品午夜视频| 亚洲福利视频三区| 一区二区三区在线视频观看58| 中文字幕视频一区二区三区久| 国产偷国产偷亚洲高清人白洁| 欧美精品一区二区精品网| 日韩你懂的电影在线观看| 欧美二区乱c少妇| 欧美日韩国产片| 欧美无人高清视频在线观看| 色婷婷精品大在线视频| 色婷婷精品大在线视频 | 色综合一区二区| 91免费国产视频网站| 91丨九色丨蝌蚪富婆spa| 99riav久久精品riav| 99久久久无码国产精品| 99视频精品免费视频| 99久久久久免费精品国产| 91在线精品一区二区三区| 99久久精品国产毛片| 99国产精品视频免费观看| 91年精品国产| 欧美色网一区二区| 欧美日韩免费观看一区三区| 欧美日韩电影在线| 欧美精品日韩一本| 日韩一区二区三区在线| 日韩欧美电影在线| 久久亚洲一区二区三区四区| 国产性做久久久久久| 日本一二三四高清不卡| 综合色天天鬼久久鬼色| 亚洲精品成人天堂一二三| 亚洲午夜在线视频| 日本色综合中文字幕| 激情成人午夜视频| 高清在线成人网| 91丝袜高跟美女视频| 欧美私人免费视频| 欧美一区二区精品久久911| 精品播放一区二区| 亚洲国产精品99久久久久久久久| 亚洲视频在线一区| 亚洲大片精品永久免费| 免费美女久久99| 国产成人av电影在线| 91美女片黄在线观看91美女| 欧美三级韩国三级日本三斤| 日韩美一区二区三区| 日本一区二区三区在线不卡| 亚洲色图一区二区三区| 亚洲自拍偷拍综合| 日韩精品1区2区3区| 国产精一品亚洲二区在线视频| 99麻豆久久久国产精品免费| 欧美日韩免费电影| 精品久久国产97色综合| 国产精品国产三级国产aⅴ原创| 一区二区三区国产精华| 蜜桃视频在线观看一区| 国产成人精品午夜视频免费| 在线看日韩精品电影| 精品欧美一区二区久久| 亚洲色图丝袜美腿| 免费看欧美女人艹b| www.亚洲激情.com| 欧美二区三区91| 中文字幕精品一区 | 亚洲最大色网站| 蜜臀久久久99精品久久久久久| 粉嫩一区二区三区在线看| 欧美亚洲精品一区| 久久精品视频一区二区三区| 夜夜爽夜夜爽精品视频| 韩国三级在线一区| 在线影视一区二区三区| 精品理论电影在线| 亚洲老司机在线| 精品午夜一区二区三区在线观看 | 欧美日韩国产一级片| 久久久精品国产99久久精品芒果| 亚洲男人都懂的| 国产在线精品一区二区不卡了 | 国产98色在线|日韩| 91精品一区二区三区在线观看| 国产精品久久三| 奇米777欧美一区二区| 99国产精品久久久久| 精品日本一线二线三线不卡| 一区二区三区日韩欧美| 国产原创一区二区| 欧美日韩国产精品成人| 国产精品亲子乱子伦xxxx裸| 久久精品国产999大香线蕉| 色www精品视频在线观看| 26uuu亚洲综合色| 午夜成人在线视频| 99精品视频中文字幕| 精品国产污污免费网站入口 | 韩国v欧美v日本v亚洲v| 欧美日韩美少妇| 日韩伦理免费电影| 国产一区二区三区四区在线观看| 欧美日韩精品免费观看视频| 中文字幕一区二区三区视频| 韩国在线一区二区| 欧美一级欧美三级| 亚洲一线二线三线久久久| 不卡高清视频专区| 久久久久久久久久电影| 奇米影视一区二区三区| 在线这里只有精品| 亚洲视频一区二区免费在线观看| 国产精品18久久久久久久久久久久 | 欧美电影精品一区二区| 亚洲第一av色| 色狠狠av一区二区三区| 中文字幕亚洲在| 国产风韵犹存在线视精品|